Oncogenic roles of lncRNA BLACAT1 and its related mechanisms in human cancers - 27/10/20
pages | 9 |
Iconographies | 3 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
LncRNA BLACAT1 exerted oncogenic roles in tumorigenesis and metastasis of cancers through post-transcriptional control or targeting downstream signalings and biological molecules. Abbreviations: ceRNA: competing endogenous RNA; VASP: vasodilator-stimulated phosphoprotein; CCR2: chemokine (C-C motif) receptor 2; ATG7: autophagy‑related protein 7; ABCB1: ATP-binding cassette subfamily B member 1; STAT3: signal transducer and activator of transcription 3; EZH2: enhancer of zeste homolog 2; PSEN1: presenilin 1.
Highlights |
• | BLACAT1 positively correlated with cellular activities and clinical implications. |
• | BLACAT1 targeted miRNAs, signalings or other biological molecules. |
• | BLACAT1 has showed its potential application for clinical interventions. |
Abstract |
Long non-coding RNAs (lncRNAs) play indispensable roles in mediating regulation of epigenetics, and their dysregulation is strongly associated with the initiation and progression of human cancers. Recently, lncRNA bladder cancer-associated transcript 1 (BLACAT1) has been observed to exert oncogenic effects on cancers, including glioma, breast cancer, lung cancer, hepatocellular carcinoma, gastric cancer, colorectal cancer, ovarian cancer, cervical cancer and osteosarcoma. Additional mechanical analyses have uncovered that lncRNA BLACAT1 is positively correlated with tumor stage, lymph node metastasis and distant metastasis of primary tumors via involvement with various cellular activities, thus leading to poor overall survival and progression-free survival (PFS). In this review, we generalize the oncogenic roles of BLACAT1 in multiple human cancers through correlation with clinical implications and cellular activities. Moreover, we forecast its potential clinical application as a novel biomarker and a promising therapeutic target for cancers.
Le texte complet de cet article est disponible en PDF.Abbreviations : lncRNA, BLACAT1, PFS, WHO, NHA, EMT, VASP, HNSCC, OSCC, PSEN1, APP, ER, PR, HER2, TNBC, TNM, TAM, ceRNA, CCR2, NSCLC, SCLC, LUAD, SCC, LCC, CT, EGFR, HCC, HBV, HCV, CCK8, GC, CRC, OXA, GES-1, ABCB1, MDR1, MRP1, LRP1, EZH2, CC, RPS15A, FIGO, MMP-7, CSCC, HPV, PTC, CHART, RIP, CLIP, UTMD, HSC, IL-6, LIF, SCF, M-CSF
Keywords : LncRNA, BLACAT1, Biomarker, Therapeutic target, Human cancers
Plan
Vol 130
Article 110632- octobre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?